Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D. James, Mahesh Parmar, Mymoona Alzouebi et al.|The Lancet|2015Cited by 2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D. James, Matthew R. Sydes, Johann S. de Bono et al.|New England Journal of Medicine|2017Cited by 1.8k
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019Silke Gillessen, Robert E. Reiter, Gerhardt Attard et al.|European Urology|2020Cited by 396
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.Nicholas D. James, Laura Murphy, Noel W. Clarke et al.|BORIS (University Library Bern)|2022Cited by 311
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021Silke Gillessen, Piet Ost, Andrew J. Armstrong et al.|European Urology|2022Cited by 131